参考文献[1]
LjungmanP, de la CamaraR, RobinC, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)[J]. Lancet Infect Dis, 2019, 19(8): e260-e272. .
[2]
HakkiM, AitkenSL, Danziger-IsakovL, et al. American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation[J]. Transplant Cell Ther, 2021, 27(9): 707-719. .
[3]
YongMK, ShigleTL, KimYJ, et al. American Society for Transplantation and Cellular Therapy Series:#4-Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation[J]. Transplant Cell Ther, 2021, 27(12): 957-967. .
[4]
GirmeniaC, LazzarottoT, BonifaziF, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies[J]. Clin Transplant, 2019, 33(10): e13666. .
[5]
LjungmanP, BoeckhM, HirschHH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials[J]. Clin Infect Dis, 2017, 64(1): 87-91. .
[6]
ChemalyRF, ChouS, EinseleH, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials[J]. Clin Infect Dis, 2019, 68(8): 1420-1426. .
[7]
BaoX, ZhuQ, XueS, et al. Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China[J]. Bone Marrow Transplant, 2016, 51(12): 1625-1627. .
[8]
XuanL, HuangF, FanZ, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies[J]. J Hematol Oncol, 2012, 5: 46. .
[9]
SunYQ, WangY, ZhangXH, et al. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation[J]. Ann Hematol, 2019, 98(8):1877-1883. .
[10]
GaoL, ZhangC, GaoL, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China[J]. J Hematol Oncol, 2015, 8: 90. .
[11]
GaoXN, LinJ, WangLJ, et al. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies[J]. Ann Hematol, 2020, 99(8): 1883-1893. .
[12]
ChangYJ, WangY, XuLP, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study[J]. J Hematol Oncol, 2020, 13(1): 27. .
[13]
LinR, WangY, HuangF, et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study[J]. BMC Med, 2019, 17(1): 156. .
[14]
ShenMZ, HongSD, WangJ, et al. A predicted model for refractory/recurrent cytomegalovirus infection in acute leukemia patients after haploidentical hematopoietic stem cell transplantation[J]. Front Cell Infect Microbiol, 2022, 12: 862526. .
[15]
ChangYJ, WuDP, LaiYR, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study[J]. J Clin Oncol, 2020, 38(29): 3367-3376. .
[16]
ZhangYY, MoWJ, ZuoYY, et al. Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study[J]. Clin Transplant, 2020, 34(3): e13810. .
[17]
YehTJ, YangCI, HuangCT, et al. Revisit of the association between cytomegalovirus infection and invasive fungal infection after allogeneic hematopoietic stem cell transplantation: a real-world analysis from a high CMV seroprevalence area[J]. J Fungi(Basel), 2022, 8(4): 408. .
[18]
DongMY, TangBI, ZhuXY, et al. Protective effects of cytomegalovirus DNA copies≥ 1000/mL for AML patients in complete remission after single cord blood transplantation[J]. Infect Drug Resist, 2020, 13:373-383. .
[19]
TongJ, SunZM, LiuHI, et al. Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China[J]. Chin J Cancer Res, 2013, 25(6): 695-703. .
[20]
ChenY, XuLP, LiuKY, et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus[J]. J Clin Virol, 2016, 75: 10-15. .
[21]
ZhaoC, ZhaoXS, XuLP, et al. Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study[J]. BMC Infect Dis, 2022, 22(1):292. .
[22]
MassoudR, GagelmannN, Fritzsche FriedlandU, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation[J]. Haematologica, 2022, 107(4): 857-867. .
[23]
LvWR, ZhouY, XuJ, et al. Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study[J]. Cancer Med, 2021, 10(23): 8497-8506. .
[24]
ChuleeraruxN, NematollahiS, ThongkamA, et al. The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: A systematic review and meta-analysis[J]. Clin Microbiol Infect, 2022, 28(3): 332-344. .
[25]
BoeckhM, NicholsWG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy[J]. Blood, 2004, 103(6): 2003-2008. .
[26]
MengXY, FuHX, ZhuXL, et al. Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation[J]. Ann Hematol, 2020, 99(11): 2659-2670. .
[27]
GoldsmithSR, AbidMB, AulettaJJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis[J]. Blood, 2021, 137(23): 3291-3305. .
[28]
SolanoC, VazquezL, GimenezE, et al. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group[J]. Am J Transplant, 2021, 21(1): 258-271. .
[29]
TakenakaK, OnishiY, MoriT, et al. Negative impact of cytomegalovirus reactivation on survival in adult patients with aplastic anemia after an allogeneic hematopoietic stem cell transplantation: a report from transplantation-related complication and adult aplastic anemia working groups of the Japan Society for Hematopoietic Cell Transplantation[J]. Transplant Cell Ther, 2021, 27(1):82. e81-82. .
[30]
LimayeAP, BabuTM, BoeckhM. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation[J]. Clin Microbiol Rev, 2020, 34(1): e00043-00019. .
[31]
FryerJF, HeathAB, MinorPD, et al. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology[J]. Biologicals, 2016, 44(4): 242-251. .
[32]
FanJ, MaWH, YangMF, et al. Real-time fluorescent quantitative PCR assay for measuring cytomegalovirus DNA load in patients after haematopoietic stem cell transplantation[J]. Chin Med J(Engl), 2006, 119(10): 871-874.
[33]
翟文静,魏嘉琳,赵明峰,等.巨细胞病毒定量PCR与pp65抗原测定监测异基因造血干细胞移植巨细胞病毒感染的比较[J].中国实验血液学杂志, 2009, 17(6): 1522-1526.
[34]
PandeA, DubberkeER. Cytomegalovirus infections of the stem cell transplant recipient and hematologic malignancy patient[J]. Infect Dis Clin North Am, 2019, 33(2): 485-500. .
[35]
JakhariaN, HowardD, RiedelDJ. CMV Infection in hematopoietic stem cell transplantation: prevention and treatment strategies[J]. Curr Treat Options Infect Dis, 2021: 1-18. .
[36]
李肃,沈再红,万理萍,等.异基因造血干细胞移植后巨细胞病毒肺炎与其他肺炎的比较研究[J].中华内科杂志, 2021, 60(6): 556-560. .
[37]
YehPJ, WuRC, ChiuCT, et al. Cytomegalovirus diseases of the gastrointestinal tract[J]. Viruses, 2022, 14(2): 352. .
[38]
HeJD, LiuYL, WangZF, et al. Colonoscopy in the diagnosis of intestinal graft versus host disease and cytomegalovirus enteritis following allogeneic haematopoietic stem cell transplantation[J]. Chin Med J(Engl), 2008, 121(14): 1285-1289.
[39]
HerfarthHH, LongMD, RubinasTC, et al. Evaluation of a non-invasive method to detect cytomegalovirus(CMV)-DNA in stool samples of patients with inflammatory bowel disease (IBD): a pilot study[J]. Dig Dis Sci, 2010, 55(4): 1053-1058. .
[40]
ZavrelovaA, RadochaJ, PliskovaL, et al. Detection of cytomegalovirus DNA in fecal samples in the diagnosis of enterocolitis after allogeneic stem cell transplantation[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(3): 227-231. .
[41]
SunYQ, XuLP, HanTT, et al. Detection of human cytomegalovirus(CMV)DNA in feces has limited value in predicting CMV enteritis in patients with intestinal graft-versus-host disease after allogeneic stem cell transplantation[J]. Transpl Infect Dis, 2015, 17(5): 655-661. .
[42]
Suárez-LledóM, MarcosMÁ, CuatrecasasM, et al. Quantitative PCR is faster, more objective, and more reliable than immunohistochemistry for the diagnosis of cytomegalovirus gastrointestinal disease in allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(11): 2281-2286. .
[43]
朱雪菲,肖艳辉,张文朋,等.造血干细胞移植患者巨细胞病毒性视网膜炎相关葡萄膜炎的临床特征[J].中华眼底病杂志, 2021, 37(7): 518-522. .
[44]
刘静,付强,王昱,等.供者巨细胞病毒血清学阴性状态对异基因造血干细胞移植患者预后影响的临床分析[J].中华内科杂志, 2021, 60(5): 459-465. .
[45]
BoeckhM, NicholsWG, ChemalyRF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial[J]. Ann Intern Med, 2015, 162(1): 1-10. .
[46]
YiES, LeeJW, KimYJ, et al. Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants[J]. Ann Hematol, 2022, 101(2): 409-419. .
[47]
MainouM, AlahdabF, TobianAA, et al. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis[J]. Transfusion, 2016, 56(6Pt 2): 1569-1580. .
[48]
MartyFM, LjungmanP, ChemalyRF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation[J]. N Engl J Med, 2017, 377(25): 2433-2444. .
[49]
BansalR, GordilloCA, AbramovaR, et al. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease[J]. Transpl Infect Dis, 2021, 23(2): e13487. .
[50]
AkahoshiY, KimuraSI, TadaY, et al. Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease[J]. Blood Adv, 2022, 6(2): 574-584. .
[51]
ReusserP, EinseleH, LeeJ, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation[J]. Blood, 2002, 99(4): 1159-1164. .
[52]
Ruiz-CampsI, LenO, de la CamaraR, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients[J]. Antivir Ther, 2011, 16(7): 951-957. .
[53]
MaertensJ, CordonnierC, JakschP, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation[J]. N Engl J Med, 2019, 381(12): 1136-1147. .
[54]
LiuKY, WangY, HanMZ, et al. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial[J]. Chin Med J(Engl), 2010, 123(16): 2199-2205. .
[55]
KaeuferleT, KraussR, BlaeschkeF, et al. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation[J]. J Hematol Oncol, 2019, 12(1): 13. .
[56]
FabrizioVA, Rodriguez-SanchezMI, MauguenA, et al. Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses[J]. Blood Adv, 2021, 5(2): 496-503. .
[57]
PeiXY, LiuXF, ZhaoXY, et al. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation[J]. Cell Mol Immunol, 2022, 19(4): 482-491. .
[58]
PeiXY, ZhaoXY, LiuXF, et al. Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy[J]. Am J Hematol, 2022, 97(6): 762-769. .
[60]
YinZ, SunJ, YangY, et al. Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation[J]. Transpl Infect Dis, 2022, 24(2): e13776. .
[61]
ErardV, GuthrieKA, SeoS, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices[J]. Clin Infect Dis, 2015, 61(1): 31-39. .
[62]
赵晓甦,刘代红,许兰平,等.异基因造血干细胞移植后巨细胞病毒肺炎临床特点分析[J].北京大学学报(医学版), 2009, 41(5): 548-553. .
[63]
YanCH, WangY, MoXD, et al. Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2020, 55(6): 1147-1160. .
[64]
BaghbanA, MalinisM. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature[J]. J Neurol Sci, 2018, 388: 28-36. .
[65]
KeP, BaoX, ZhouJ, et al. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation[J]. Hematology, 2020, 25(1): 43-47. .
[66]
AlonsoL, RudillaF, GimenoR, et al. Successful treatment of post-transplant CMV meningoencephalitis with third-party CMV virus-specific T cells: Lessons learned[J]. Pediatr Transplant, 2019, 23(8): e13584. .